TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2928998

Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol (400, 600, and 800 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled isoprenaline (400, 600, and 800 micrograms)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (400, 600, and 800 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30029716

Group type: EXPERIMENTAL
Intervention: Group counseling based on Bandura's self-efficacy theory (six 90-minute sessions over six weeks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study: 26316325

Group type: EXPERIMENTAL
Intervention: Epratuzumab (1,200 mg infusions at weeks 0 and 2 of repeating 12-week cycles) plus standard of care
Number of subjects: 203
Study: 25867771

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg qd
Number of subjects: 162

Group type: COMPARATOR
Intervention: NPH insulin qd
Number of subjects: 162
Study: 23673304

Group type: EXPERIMENTAL
Intervention: Continuous Terbinafine (CTERB)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Intermittent Terbinafine (TOT)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pulsed Itraconazole (III)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combined therapy (COMBO)
Number of subjects: 106
Study: 20608826

Group type: EXPERIMENTAL
Intervention: Treatment of depression in patients with heart disease; specific intervention details not available.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recognition and treatment of depression; specific intervention details not available.
Number of subjects: 0
Study: 18656572

Group type: EXPERIMENTAL
Intervention: Hispanic breast cancer survivors
Number of subjects: 330

Group type: COMPARATOR
Intervention: Non-Hispanic white breast cancer survivors
Number of subjects: 330
Study: 16204787

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 0
Study: 12598069

Group type: EXPERIMENTAL
Intervention: Active biventricular pacing
Number of subjects: 30
Study: 10521635

Group type: EXPERIMENTAL
Intervention: Lateral glide treatment technique
Number of subjects: 8
Study: 8904624

Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1679870

Group type: EXPERIMENTAL
Intervention: Oral ciprofloxacin and aerosol inhalations of colistin twice daily for 3 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: No anti-pseudomonas chemotherapy
Number of subjects: 26
Study: 6214611

Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 30697730

Group type: EXPERIMENTAL
Intervention: PMT+Emotional Engagement (EE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: PMT+Child Centred Play (CCP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both interventions (PMT+EE and PMT+CCP)
Number of subjects: 40
Study: 27834590

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 27
Study: 24304555

Group type: EXPERIMENTAL
Intervention: Individualized Positive Psychosocial Intervention (IPPI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Attention Control (AC)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 180
Study: 23975842

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (666 IU/day)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (no cholecalciferol)
Number of subjects: 101
Study: 22559269

Group type: EXPERIMENTAL
Intervention: Prophylactic intra-graft administration of abciximab and verapamil followed by direct stenting (n=91)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Conventional PCI technique (n=72)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (n=72)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Novel strategy group (n=91)
Number of subjects: 163
Study: 19280232

Group type: EXPERIMENTAL
Intervention: Bone substitutes (allografts, ceramics, demineralized bone matrix, osteoinductive factors, autogenous platelet concentrate, mesenchymal stem cells, gene therapy)
Number of subjects: 0
Study: 15741528

Group type: EXPERIMENTAL
Intervention: Distal microcirculatory protection system during PCI
Number of subjects: 501

Group type: COMPARATOR
Intervention: Angioplasty without distal protection
Number of subjects: 501
Study: 12556375

Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin (one dose)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 750 mg ciprofloxacin (two doses every 12 hours)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (nonvitrectomized eyes)
Number of subjects: 30
Study: 10997367

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Thickened formula (0.4 g galactomannan per 100 ml diluted milk)
Number of subjects: 47
Study: 8844273

Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 1 degree
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 4 degrees
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Treadmill inclination at 7 degrees
Number of subjects: 10
Study: 1950094

Group type: EXPERIMENTAL
Intervention: Trivalent split influenza vaccine
Number of subjects: 149

Group type: COMPARATOR
Intervention: Trivalent subunit influenza vaccine
Number of subjects: 149
Study: 6525242

Group type: EXPERIMENTAL
Intervention: Intravenous diazepam
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous hyoscine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study: 29921088

Group type: EXPERIMENTAL
Intervention: PVC DLT (n = 54)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Silicone DLT (n = 54)
Number of subjects: 108
Study: 28092404

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice a day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Myoinositol (1000 mg twice a day)
Number of subjects: 34
Study: 25638326

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (15 mg/kg intravenously on day 1 or 2)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 390
Study: 24408124

Group type: EXPERIMENTAL
Intervention: Nasal nitric oxide measurement in allergic rhinitis
Number of subjects: 175

Group type: COMPARATOR
Intervention: Nasal nitric oxide measurement in nonallergic rhinitis
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Correlation of nasal nitric oxide with sinus ostial obstruction in allergic rhinitis
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Correlation of nasal nitric oxide with opacification score in allergic rhinitis
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Correlation of nasal nitric oxide with eosinophil count in allergic rhinitis
Number of subjects: 175
Study: 21948313

Group type: EXPERIMENTAL
Intervention: Endotrol(®) ETT with McGrath(®)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endotrol(®) ETT with GlideScope(®)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GlideRite(®)‐styletted standard ETT with McGrath(®)
Number of subjects: 60

Group type: COMPARATOR
Intervention: GlideRite(®)‐styletted standard ETT with GlideScope(®)
Number of subjects: 60
Study: 20014908

Group type: EXPERIMENTAL
Intervention: Fu-Yuan Pellet (FYP)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Lofexidine
Number of subjects: 225
Study: 17306016

Group type: EXPERIMENTAL
Intervention: Bolus hydrocortisone (200 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continuous hydrocortisone infusion (200 mg/day)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 16047507

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 2097

Group type: EXPERIMENTAL
Intervention: HUI(3)
Number of subjects: 2097

Group type: EXPERIMENTAL
Intervention: HUI(2)
Number of subjects: 2097

Group type: EXPERIMENTAL
Intervention: SF-6D
Number of subjects: 2097

Group type: EXPERIMENTAL
Intervention: eQWB
Number of subjects: 2097

Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 2097
Study: 12887471

Group type: EXPERIMENTAL
Intervention: Serum protein analysis using SELDI technique
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 17.5 kDa protein abundance in stage T1 prostate cancer
Number of subjects: 35
Study: 10381298

Group type: EXPERIMENTAL
Intervention: Fluvastatin treatment for 52 weeks
Number of subjects: 79
Study: 8730228

Group type: EXPERIMENTAL
Intervention: Diazepam (four logarithmically increasing doses)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (four logarithmically increasing doses)
Number of subjects: 50
Study: 1888825

Group type: EXPERIMENTAL
Intervention: ranitidine (300 mg nocte)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: cimetidine (800 mg nocte)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: famotidine (40 mg nocte)
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 6337578

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride with behavior therapy (BT)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo with behavior therapy (BT)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride with supportive psychotherapy
Number of subjects: 218

Group type: COMPARATOR
Intervention: Supportive psychotherapy with placebo
Number of subjects: 218
Study: 31141427

Group type: EXPERIMENTAL
Intervention: Cooling over the anterior thigh
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cooling over the knee joint
Number of subjects: 12
Study: 30247524

Group type: EXPERIMENTAL
Intervention: Bevacizumab (B) added to chemotherapy (capecitabine (C)±mitomycin (M))
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: CMS classification
Number of subjects: 237

Group type: COMPARATOR
Intervention: Bevacizumab (B) added to first-line capecitabine-based chemotherapy
Number of subjects: 237
Study: 25896863

Group type: EXPERIMENTAL
Intervention: Case-based training programme for general practitioners
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 25296334

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3) 50,000 IU/week
Number of subjects: 96

Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 96
Study: 21914653

Group type: EXPERIMENTAL
Intervention: Acceptance-based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Change-based intervention
Number of subjects: 0
Study: 20521904

Group type: EXPERIMENTAL
Intervention: Traditional worksite health promotion program
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Activated consumer program
Number of subjects: 631

Group type: COMPARATOR
Intervention: Control arm (not specified)
Number of subjects: 631
Study: 17915999

Group type: EXPERIMENTAL
Intervention: Surgery plus 3 days of AZM, 500 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgery plus 3 days of placebo
Number of subjects: 30
Study: 16105155

Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 125

Group type: COMPARATOR
Intervention: NPH
Number of subjects: 125
Study: 12114037

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (600 mg vitamin E, 250 mg vitamin C, and 20 mg beta‐carotene daily)
Number of subjects: 20536

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20536
Study: 10193713

Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Irbesartan 150 mg
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Irbesartan (all doses)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Irbesartan (75 mg and 150 mg)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 218
Study: 7474602

Group type: EXPERIMENTAL
Intervention: Bilateral orchiectomy and 25 mg/day of etoposide every 2 weeks for 6 months
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Bilateral orchiectomy and 560 mg/day of estramustine phosphate for 6 months
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bilateral orchiectomy alone
Number of subjects: 44
Study: 2148504

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg once daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Methyldopa 250 mg twice daily
Number of subjects: 27
Study: 108152

Group type: EXPERIMENTAL
Intervention: Phyllocontin tablets (12.5 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Phyllocontin tablets (12.5 mg/kg twice daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29322619

Group type: EXPERIMENTAL
Intervention: BP-SES
Number of subjects: 2737

Group type: COMPARATOR
Intervention: DP-SES
Number of subjects: 2737
Study: 27306264

Group type: EXPERIMENTAL
Intervention: Acetazolamide during altitude sojourn at 2590 m
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo during altitude sojourn at 2590 m
Number of subjects: 39
Study: 25909149

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus gasseri KS‐13, Bifidobacterium bifidum G9‐1, and Bifidobacterium longum MM2)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23843441

Group type: EXPERIMENTAL
Intervention: Highest quartile of long-chain ω‐3 polyunsaturated fatty acids (LCω‐3PUFA)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Higher linoleic acid (ω‐6)
Number of subjects: 834
Study: 20965387

Group type: EXPERIMENTAL
Intervention: Spaced education (four isomorphic cycles of nine e‐mails over 36 weeks)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Spaced education (continued after intervention)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control (continued after intervention)
Number of subjects: 95
Study: 17853036

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg intravenously 60 min before the procedure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg intravenously 60 min before the procedure
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study: 16027246

Group type: EXPERIMENTAL
Intervention: Dark chocolate (DC) 100 g per day (containing 88 mg flavanols)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dark chocolate (DC) 100 g per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flavanol-free white chocolate (WC) 90 g per day
Number of subjects: 20
Study: 14619611

Group type: EXPERIMENTAL
Intervention: Diet with lower glycaemic index
Number of subjects: 0
Study: 10643800

Group type: EXPERIMENTAL
Intervention: Caffeine (100 mg) and placebo beverage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Placebo pill and alcohol (0.55 g/kg in 10% (v/v) solution)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo pill and placebo beverage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both caffeine and alcohol
Number of subjects: 12
Study: 8865536

Group type: EXPERIMENTAL
Intervention: Protein C, Antithrombin III, Heparin-Cofactor II, and plasminogen levels
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Menopause status
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Pill use
Number of subjects: 4000

Group type: COMPARATOR
Intervention: PT and PTT ratio, gender, age, smoking, body-mass index, HDL cholesterol, blood group
Number of subjects: 4000
Study: 6528679

Group type: EXPERIMENTAL
Intervention: UVA blood irradiation
Number of subjects: 92

Group type: COMPARATOR
Intervention: Citrate infusion
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 92
Study: 31060042

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Both SSRIs and CBT
Number of subjects: 55
Study: 29652271

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 μg/kg/min) administered preoperatively for 24 hours including intraoperative period
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no levosimendan)
Number of subjects: 60
Study: 24894735

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (3 × 1 h weekly sessions)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Dissonance-based intervention (3 × 1 h weekly sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 44
Study: 24960268

Group type: EXPERIMENTAL
Intervention: Remote robotic navigation (RRN)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Manual ablation
Number of subjects: 157
Study: 22728005

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention with optimal medical therapy
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 2201
Study: 20861588

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: COMPARATOR
Intervention: Quotient™ ADHD System (QGSS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lin's concordance correlation coefficient for QGSS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lin's concordance correlation coefficient for ADHD-RS Total score
Number of subjects: 30
Study: 19024339

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 40
Study: 16009170

Group type: EXPERIMENTAL
Intervention: Ringer's lactate instillation (300 mL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (no fluid instillation)
Number of subjects: 36
Study: 12406833

Group type: EXPERIMENTAL
Intervention: Mepolizumab (750 mg, three intravenous doses over 20 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11762559

Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole 200 mg twice daily for 2 days, then once daily for 5 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution 200 mg twice daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Oral itraconazole solution 200 mg once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Overall treatment with itraconazole
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravenous itraconazole
Number of subjects: 32
Study: 9205678

Group type: EXPERIMENTAL
Intervention: Pulse cyclophosphamide and prednisolone (PCYP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Continuous oral prednisolone and cyclophosphamide followed by azathioprine (CCAZP)
Number of subjects: 54
Study: 7679560

Group type: EXPERIMENTAL
Intervention: Morphine (0.16 mg.kg‐1)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Diamorphine (0.08 mg.kg‐1)
Number of subjects: 38
Study: 2887152

Group type: EXPERIMENTAL
Intervention: Vigabatrin (2 to 3 g/d, stratified according to weight)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Vigabatrin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 31434737

Group type: EXPERIMENTAL
Intervention: DNA/rAd5 HIV vaccine regimen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined Env‐specific CD8+ T-cell polyfunctionality score and IgG response
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-gp140 antibody-dependent cellular phagocytosis
Number of subjects: 0
Study: 28287949

Group type: EXPERIMENTAL
Intervention: Participatory community theater (CT) dramas
Number of subjects: 1200
Study: 27132450

Group type: EXPERIMENTAL
Intervention: Midazolam 1 μg x kg(‐1) x min(‐1) for sedation and 1 mg/mL remifentanil for analgesia with 0.05 mg/kg intravenous bolus, then continuous infusion of 0.02‐0.10 mg x kg(‐1) x h(‐1)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Midazolam for sedation only (control group)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Midazolam 1 μg x kg(‐1) x min(‐1) for sedation and 1 mg/mL remifentanil for analgesia
Number of subjects: 140
Study: 23440308

Group type: EXPERIMENTAL
Intervention: SCORES after-school program
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 156
Study: 21280081

Group type: EXPERIMENTAL
Intervention: 200mg entacapone
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 20032543

Group type: EXPERIMENTAL
Intervention: 12-16 weeks of pegylated interferon and ribavirin treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: 24 weeks of pegylated interferon and ribavirin treatment
Number of subjects: 8
Study: 16515966

Group type: EXPERIMENTAL
Intervention: Hand assisted procedure
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Transperitoneal procedure
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Retroperitoneal procedure
Number of subjects: 33
Study: 12720508

Group type: COMPARATOR
Intervention: Cold vaccine (no deliberate warming)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Warmed vaccine (37 degrees C incubator)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Rubbed vaccine (rubbed between palms for 1 minute)
Number of subjects: 150
Study: 10934803

Group type: COMPARATOR
Intervention: CEOV therapy (cyclophosphamide, epirubicin, vincristine, etoposide)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CEOV-CAM therapy (cyclophosphamide, ACNU, methotrexate)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CEOV-CAM therapy (limited disease)
Number of subjects: 150

Group type: COMPARATOR
Intervention: CEOV therapy (limited disease)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Patients receiving thoracic irradiation after response
Number of subjects: 150

Group type: COMPARATOR
Intervention: CEOV arm (tumor recurrence)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: CEOV-CAM arm (tumor recurrence)
Number of subjects: 150
Study: 9346173

Group type: EXPERIMENTAL
Intervention: High-intensity, low-distance program (E)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual program (C)
Number of subjects: 96